 | Up a level |
2022
Kruger, S. F., Lohneis, A., Abendroth, A., Berger, A. W., Ettrich, T. J., Waidmann, O., Kapp, M., Steiner, B., Kumbrink, J., Reischer, A., Haas, M., Westphalen, C. B., Zhang, D., Miller-Phillips, L., Burger, P. J., Kobold, S., Werner, J., Subklewe, M., Von Bergwelt-Baildon, M., Kunzmann, V, Seufferlein, T., Siveke, J. T., Sinn, M., Heinemann, V, Ormanns, S. and Boeck, S. (2022). Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study. ESMO Open, 7 (1). AMSTERDAM: ELSEVIER. ISSN 2059-7029
2021
Haas, M., Waldschmidt, D. T., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., von Weikersthal, L. Fischer, Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R., Malfertheiner, P., Illerhaus, G., Kubicka, S., Abdul-Ahad, A., Snijder, R., Kruger, S., Westphalen, C. B., Held, S., Von Bergwelt-Baildon, M., Boeck, S. and Heinemann, V (2021). Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method. Eur. J. Cancer, 146. S. 95 - 107. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
2018
Haas, M., Loupy, A., Lefaucheur, C., Roufosse, C., Glotz, D., Seron, D., Nankivell, B. J., Halloran, P. F., Colvin, R. B., Akalin, Enver, Alachkar, N., Bagnasco, S., Bouatou, Y., Becker, J. U., Cornell, L. D., van Huyen, J. P. Duong, Gibson, I. W., Kraus, Edward S., Mannon, R. B., Naesens, M., Nickeleit, V., Nickerson, P., Segev, D. L., Singh, H. K., Stegall, M., Randhawa, P., Racusen, L., Solez, K. and Mengel, M. (2018). The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am. J. Transplant., 18 (2). S. 293 - 308. HOBOKEN: WILEY. ISSN 1600-6143
Haas, M., Waldschmidt, D., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R. J. C., Malfertheiner, P., Illerhaus, G., Kubicka, S., Held, S., Westphalen, C. B., Kruger, S., Boeck, S. and Heinemann, V. (2018). Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT). Ann. Oncol., 29. S. 243 - 244. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
2017
Loupy, A., Haas, M., Solez, K., Racusen, L., Glotz, D., Seron, D., Nankivell, B. J., Colvin, R. B., Afrouzian, M., Akalin, E., Alachkar, N., Bagnasco, S., Becker, J. U., Cornell, L., Drachenberg, C., Dragun, D., de Kort, H., Gibson, I. W., Kraus, E. S., Lefaucheur, C., Legendre, C., Liapis, H., Muthukumar, T., Nickeleit, V., Orandi, B., Park, W., Rabant, M., Randhawa, P., Reed, E. F., Roufosse, C., Seshan, S. V., Sis, B., Singh, H. K., Schinstock, C., Tambur, A., Zeevi, A. and Mengel, M. (2017). The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. Am. J. Transplant., 17 (1). S. 28 - 42. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-6143